Palvella Therapeutics Announces Pricing of Upsized Public Offering

Impact · against what's priced in

Palvella Therapeutics is raising $200 million through a public offering to fund its QTORIN pipeline. While the capital infusion secures the company's clinical runway, the immediate effect is diluted share value due to the issuance of 1.6 million new shares.

PVLA+0.10

No priced-in read yet

In context

The company is raising $200 million to fund the QTORIN rapamycin and pitavastatin programs, balancing the negative impact of share dilution with a significantly strengthened balance sheet for R&D.

Read from the article alone

• equity financingNew
• healthcare
• PVLA
• biopharma
• biotechnology
• capital raise
• public offering
• rare diseases

Top 1 mover · tap to explore